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Abstract
Background: Tuberculosis (TB) is a major cause of death in HIV patients worldwide. Here we describe the
epidemiology and outcome of HIV-TB co-infections in a high-income country with low TB incidence and integrated
HIV and TB therapy according to European guidelines.
Methods: This study was based on the HIV cohort of the Helsinki University Hospital which includes all HIV patients
in the Helsinki region with a population of 1.5 million. Totally, 1939 HIV-positives who have been under follow-up
between 1998 and 2015 were included.
Results: TB was diagnosed in 53 (2.7%) of the HIV-patients. The TB incidence rate was higher in injecting drug users
(IRR 3.15; 95% CI 1.33–7.52) and heterosexuals (IRR 3.46; 95% CI 1.64–7.29) compared to men having sex with men.
The incidence rate was also higher in those born in Sub-Saharan Africa (IRR 3.53; 95% CI 1.78–7.03) compared to
those born in Finland. There was a significant reduction in the total TB incidence rate of 59% per 6-year period
between 1998 and 2015 (p < 0.001). In injecting drug users there was a reduction in incidence rate from 1182 to 88
per 100,000 (p < 0.001) and in people born in Sub-Saharan Africa from 2017 to 195 per 100,000 (p < 0.001). Among
the 53 HIV-TB co-infected cases, one female and 15 males died during follow up. HIV was the primary cause of
death in five patients but none of the deaths were caused by TB.
Conclusion: The incidence rate of tuberculosis among HIV-positives in Finland has been declining between 1998
and 2015. Among injecting drug users, the reduction is probably explained by harm reduction interventions and care
in comprehensive care centers in Helsinki. The increased coverage of antiretroviral therapy is probably another main
reason for the decline in TB incidence rates. Despite good treatment results for both HIV and TB, the all-cause mortality
among Finnish males with HIV-TB was high, and common causes of death were intoxications and suicides.
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Background
Tuberculosis (TB) is the most common opportunistic
infection in HIV-positive patients. HIV-TB co-infection
was estimated to affect 1.2 million people worldwide in
2015, and to cause 400,000 deaths [1]. HIV-positives are
20–40 times more likely to develop active TB infection
compared to HIV-negatives [2]. The most important risk
factors for developing active tuberculosis among
HIV-positives are low CD4 count, living in high
TB-incidence regions and absence of antiretroviral
therapy [3–5].
High mortality has been reported in HIV-TB patients
in Africa, particularly in patients with advanced disease
[6]. In Africa, Asia and Eastern Europe the leading cause
of death has been TB. Data about the outcome of
HIV-TB co-infections in high-income countries has been
limited. A multi-centre study showed that among
patients from Western Europe and Argentina, 50% of
the deaths during the first three months after the TB
diagnosis were TB-related [7]. For patients who died at a
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later stage the cause of death was predominantly
non-TB-related or unknown.
A Cochrane review of 12 randomized treatment trials
of latent TB infection in HIV-positives showed a 32% re-
duction of the incidence of active TB [8]. The reduction
was 62% in those with positive tuberculin skin test
(TST). Overall, there was no evidence that TB prevent-
ive therapy versus placebo reduced all-cause mortality.
The need for treatment of latent tuberculosis infection
(LTBI) in high-income countries has remained contro-
versial. The WHO [9] and US [10] guidelines recom-
mend testing of all HIV-positives for LTBI and
treatment of all patients with positive result in interferon
gamma release assays (IGRA) or tuberculin skin test.
EACS [11] and BHIVA guidelines [12] recommend
IGRA-testing and medication only after risk assessment
based on CD4 count, country of origin and length of
previous antiretroviral therapy. Despite recommenda-
tions for treatment of LTBI, the implementation of this
strategy has been limited in high-income countries [4].
The aim of this study was to describe in detail the in-
cidence of TB among HIV-positives and the outcomes




This is a retrospective register study based on the cohort
of HIV-patients registered for follow up at the Infectious
Disease Clinic of the Helsinki University Hospital. This
is the only HIV clinic in the Helsinki region in Southern
Finland with a population of 1.5 million people, where
63% of all HIV patients in Finland have been diagnosed.
The treatment of HIV and tuberculosis is integrated and
free of charge for patients living in Finland.
All 1939 patients in the Helsinki HIV Cohort between
1st January 1998 and 31st December 2015 were included
in this study. Classified as HIV-TB co-infections were 53
patients diagnosed with an active TB infection in Finland
between 1995 and 2015. We excluded four patients,
whose tuberculosis diagnosis were made abroad before
migrating to Finland.
Data sources
The InfCare HIV database (RealQ platform, Health Solu-
tions, Sweden) of the Helsinki HIV Cohort has provided
the basic data about the patients and details about the
TB diagnosis and outcome have been collected from the
electronic patient records (Uranus, CGI, Canada) and
laboratory database of the Helsinki University Hospital.
The categorical variables obtained from the databases
were: sex, mode of HIV transmission, country of birth,
outcome of TB treatment (WHO classification), MDR
TB diagnosed, MAC co-infection diagnosed, AIDS
defining diagnoses. The continuous variables obtained
were: date of birth, date of death, date of TB diagnosis,
date of HIV diagnosis, dates of TB treatment, date of
initiation of HIV treatment, CD4 at time of TB diagno-
sis, CD4 nadir. All new HIV and TB infections in
Finland are reported to the National Infectious Disease
Register, and from there we have confirmed that all
co-infections in the Helsinki region are included in this
study. The causes of death were obtained from Statistics
Finland.
Genotyping of Mycobacterium tuberculosis isolates
Genotyping was performed with the spoligotyping tech-
nique as previously described [13]. The spoligotypes
were assigned to international SIT types available in the
SITVITWEB database [14] [15]. For spoligotypes for
which a SIT code was not available, a local F (Finnish)
code was given.
Statistics
For the statistical calculations, the SPSS Statistics soft-
ware version 20 (IBM Corporation, NY, USA) and Stata
15.1 (StataCorp LLC, TX, USA) were used. Incidence
rates and incident rate ratios and their 95% confidence
intervals were calculated using Mantel-Haenszel
methods. Score test was used to estimate trends of rates
of change in incidence between the different 5-year pe-
riods. In the survival analyses of HIV-TB cases Log-rank
test was used to calculate p-values for categorical
variables and Wald test (Cox model) for continuous
variables. Hazard ratios and their 95% confidence inter-
vals were calculated using Cox model. Kaplan-Meier
plots were used to show estimations of the probability of




In the patients of the Helsinki HIV cohort there were 53
active TB infections diagnosed in Finland between 1995
and 2015 (Fig. 1). The annual number of new HIV-TB
co-infections have mainly been between 1 and 5 in the
Hospital District of Helsinki and Uusimaa (HUS) with a
population of 1.5 million inhabitants. The annual
number of new HIV-infections in the same district has
remained stable at a level of about 100 (Fig. 1). The new
TB cases have slowly been decreasing from 150 to 100
annually (Fig. 1).
Baseline data
Between 1998 and 2015 there were 1939 HIV-positives
on regular follow up in our cohort (Table 1). Among the
HIV-TB cases, the place of birth was Finland in 25 cases
and Sub-Saharan Africa in 12 cases. The countries of
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birth seen in those classified as others were Thailand in
9 cases, Estonia in two cases, Germany in one case,
Lithuania in one case and Egypt in one case. The mean
CD4 counts at the time of TB diagnosis for the different
subgroups presented in Table 1 were the following:
males 196 cells per cubic millimetre (range 5–854),
females 241 (9–859), IDU 183 (5–634), MSM 303 (10–
854), heterosex 194 (9–859), place of birth Finland 221
(5–854), place of birth Sub-Saharan Africa 220 (19–541),
place of birth other 146 (9–561).
Incidence rates
The incidence rates of TB in different subgroups of
HIV-positives are shown in Table 1. The incidence rates
in the range of 100–700 cases per 100,000 population
are very high compared to the current general TB
Fig. 1 Trends in HIV and TB incidences in Southern Finland. Annual numbers of HIV and TB cases in the Hospital District of Helsinki and Uusimaa in
Southern Finland between 1995 and 2015 (left Y-axis). The number of HIV-TB co-infections in the same district are shown by the bars (right Y-axis)





Person yearsa Incidence rate (95% CI) Incidence rate ratio
Total 1939 53 0.1708 310.3 (237.1–406.2)
Sex
Female 534 (27.5) 18 (34.0) 0.0471 382.3 (240.8–606.7) 1.35 (0.77–2.39)
Male 1405 (72.5) 35 (66.0) 0.1237 282.9 (203.1–394.1) 1
Mode of transmission
IDU 107 (6.4) 12 (24.0) 0.0671 407.5 (231.4–717.6) 3.15 (1.33–7.52)
MSM 755 (45.1) 9 (18.0) 0.0697 129.1 (67.2–248.0) 1
Heterosex 811 (48.5) 30 (60.0) 0.0294 446.9 (312.5–639.3) 3.46 (1.64–7.29)
Place of birth
Finland 1320 (68.3) 25 (47.2) 0.1284 194.7 (131.5–288.1) 1
Sub-Saharan Africa 249 (12.9) 12 (22.6) 0.0174 687.7 (390.6–1210.9) 3.53 (1.78–7.03)
Other 363 (18.8) 15 (28.3) 0.0233 644.3 (388.4–1068.7) 3.31 (1.75–6.29)
Died during follow-up 226 16
Age at HIV diagnosis, years, median (range) 33.9 (0–75) 35.4 (6–61)
Age at start of follow-up, years, median (range) 35.9 (6–75) 35.7 (6–61)
aTime at risk in years per 100,000 persons
Baseline data of all patients in the Helsinki HIV cohort between 1998 and 2015 compared to those in the cohort who developed TB co-infection during follow up.
Incidence rates and rate ratios of different subgroups were calculeted with the Mentel-Haenszel method
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incidence rate of 5 cases per 100,000 in Finland. The TB
incidence rate was higher in injecting drug users (IDU)
and heterosexuals compared to men having sex with
men (MSM). The incidence was lower in those born in
Finland compared to migrants from Sub-Saharan Africa
and other countries.
To analyze for temporal changes the TB incidence
rates were analyzed in 5-year periods (Table 2). This
showed a statistically significant reduction in incidences
with a 59% decrease per 5-year period, as the incidence
rate dropped from 691 to 130 per 100,000. The inci-
dence rate declined significantly in all subgroups, except
for in females and in those with country of origin other
than Finland or Sub-Saharan Africa. In IDUs, almost all
of whom were men from Finland, there was a remark-
able reduction in in the incidence rate from 1182 to 88
per 100,000 (p = 0.0009, score test for trend of rates).
Genotyping of M. Tuberculosis isolates
M. tuberculosis isolates were available for 38 of the 53
active TB cases, and were successfully genotyped
(Table 3). The most common spoligotypes were SIT53
and SIT42, with 7 and 5 cases each. Both of those in-
cluded small clusters among IDUs born in Finland with
active TB infection between years 2000–2003. Based on
genotypes, most of the other TB infections were spor-
adic cases of activation of latent TB infection obtained
in the country of origin. There were no signs that M.
tuberculosis strains from Russia or Estonia would have
caused transmission chains among HIV-positives in
Finland.
Outcomes
The 53 HIV-TB co-infected patients were classified
(Table 4) according to WHO’s definition of tuberculosis
treatment outcomes [1]. Three of the patients died
during the TB treatment and 13 after the treatment.
Classified as treatment completed or cured were 66.0%
of the cases. In 22.6% of the cases data of outcome was
not available due to transfer out or other reasons. The
average length of TB treatment was 11.7 months.
Mortality and causes of death
In the Helsinki HIV cohort, 16 (30.2%) TB co-infected
patients died during an average follow-up time of 8.8
years (Table 5). One female and 15 males died during
follow-up and this difference was statistically significant
(p 0.031, Log-rank test). There was a non-significant
trend towards higher risk of death for cases born in
Finland and in those who were diagnosed with TB more
than 6months after the moment of the HIV diagnosis.
Five of the HIV patients had both M. tuberculosis and
nontuberculous mycobacterium (NTM) infection at the
same time. Three of those were M. avium, one M.
abscessus, and one M. malmoense. Two of the patients
had M. avium cultured from the blood. M. malmoense
was detected from sputum culture. M. abscessus was
detected by culture from a lymph node biopsy sample.
One of the patients with M. avium in sputum culture
samples died during follow-up, the other four with
NTM were alive at the end of follow-up.
To explore the reasons for death of the 16 HIV-TB
co-infected patients, we analysed the ICD-10 diagnoses
of the underlying cause of death from Statistics Finland.
None of the deaths were directly related to the previous
TB infection. Five patients had HIV as primary cause of
death, with the direct cause of death being M. avium in-
fection, pulmonary hypertension, pneumonia, and
non-Hodgkin lymphoma for two patients. Seven patients
had deaths caused by intoxication or suicide. One died
of coronary disease, one of alcoholic liver cirrhosis, one
of sub-arachnoid bleeding, and in one case the cause of
death remained unknown. Thirteen of the 22 Finnish
males with HIV-TB co-infection died during follow-up
(59%). Six of these deaths were intoxications or suicides
(46%).
The causes of deaths were also classified using the
algorithms developed by the Coding of Death in HIV
(CoDe) Project related to the EuroSIDA study [16].
Based on these algorithms, 4–6 of the 16 deaths were
classified as AIDS-related, as compared to the 5 deaths
with HIV as primary cause of death according to the
ICD-10 diagnose in the death certificate.
Discussion
During the last 20 years, the HIV incidence in Finland
has been slightly increasing, mainly because of immigra-
tion from Africa and Asia. The tuberculosis incidence
has been gradually decreasing, as the number of elderly
people with exposure in childhood has declined.
The decline in the incidence of tuberculosis among
HIV-infected shown in this study was expected. A com-
prehensive care center for marginalized HIV-infected
IDUs was started in December 2000 [17]. The outbreak
of HIV among IDUs in the Helsinki region was
contained in a couple of years after the start of the care
center [18]. A symptom-based interview of the clients of
the care center was carried out in 2002 after the fourth
case of tuberculosis among IDUs was identified. The
interview yielded one additional case of tuberculosis.
We do not have a definite explanation for the decline
in tuberculosis incidence among people from
Sub-Saharan Africa. However, the increase in antiretro-
viral therapy coverage may have played a central role.
The coverage of antiretroviral therapy among people
from Sub-Saharan Africa in our clinical database has
been rising continuously, in 1998 63%, in 2005 65%, in
2010 74%, and in 2015 93% (unpublished data).
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Table 2 Incidence rates of TB divided into three 6-year periods
Events Person yearsa Incidence rate (95% CI) Score test for trend of rates P-value
Rate ratio (95% CI)
Total 0.41 (0.29–0.59) < 0.001
1998–2003 22 0.0318 691.2 (455.1–1049.7)
2004–2009 20 0.0543 368.5 (237.7–571.1)
2010–2015 11 0.0847 129.9 (71.9–234.5)
Sex
Female 0.57 (0.31–1.04) 0.068
1998–2003 6 0.0086 698.7 (313.9–1555.3)
2004–2009 6 0.0144 416.9 (187.3–928.0)
2010–2015 6 0.0241 248.8 (111.8–553.9)
Male 0.35 (0.23–0.54) < 0.001
1998–2003 16 0.0232 688.4 (421.8–1123.7)
2004–2009 14 0.0399 351.0 (207.9–592.6)
2010–2015 5 0.0606 82.5 (34.4–198.3)
Mode of transmission
IDU 0.29 (0.14–0.60) < 0.001
1998–2003 8 0.0068 1182.2 (591.2–2363.9)
2004–2009 3 0.0113 265.0 (85.5–821.6)
2010–2015 1 0.0114 88.0 (12.4–625.0)
MSM 0.19 (0.08–0.45) < 0.001
1998–2003 6 0.0132 454.3 (204.1–1011.2)
2004–2009 3 0.0220 136.4 (44.0–423.0)
2010–2015 0 0.0345 0
Heterosex 0.35 (0.23–0.54) < 0.001
1998–2003 8 0.0113 709.5 (354.8–1418.6)
2004–2009 13 0.0196 663.0 (385.0–1141.8)
2010–2015 9 0.0362 248.3 (129.2–477.3)
Place of birth
Finland 0.30 (0.18–0.49) < 0.001
1998–2003 15 0.0264 567.2 (342.0–940.9)
2004–2009 7 0.0427 163.9 (78.1–343.7)
2010–2015 3 0.0593 50.6 (16.3–156.9)
Sub-Saharan Africa 0.27 (0.12–0.59) < 0.001
1998–2003 5 0.0025 2017.2 (839.6–4846.4)
2004–2009 5 0.0047 1063.1 (442.5–2554.1)
2010–2015 2 0.0103 194.8 (48.7–778.9)
Other 0.50 (0.24–1.05) 0.066
1998–2003 2 0.0024 829.0 (207.3–3314.7)
2004–2009 8 0.0063 1261.5 (630.9–2522.5)
2010–2015 5 0.0145 344.2 (143.3–826.9)
aTime at risk in years per 100,000 persons
Here the incidence rates of TB cases in the HIV cohort are shown divided into three 6-year periods. Score test for trend of rates shows the change in incidence
between the 6-year periods. Rate ratios and 95% confidence intervals are calculated with the Mantel-Haenszel method
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The genotypes of the Mycobacterium tuberculosis
strains showed that imported TB cases have not caused
chains of infections among HIV-patients in Finland.
Most TB infections in migrants have been activations of
latent tuberculosis infections received in the country of
birth. Only two small clusters (SIT53 and SIT42) among
Finnish IDUs in the beginning of the 2000s could be
recognized. This suggests that TB infections in
HIV-positives in Finland are mostly diagnosed and
treated at an early stage and do not cause a significant
public health concern.
The rate of successful treatment of TB was 66% in our
Finnish cohort. This can be compared to WHO’s global
numbers of treatment success rate of 88% for
HIV-negative and 74% for HIV-positive TB-patients [1].
In Europe, the success rate for all TB treatments has
increased from 67 to 75% between 1995 and 2012. For
new HIV-positive TB-cases registered in Europe in 2013
the TB treatment success rate was 47% in a cohort of
9504 patients. In both the European region and the
Region of the Americas, 19% of HIV-positive TB patients
died during treatment, compared with just over 5% of
HIV-negative TB patients.
A study from Uganda with 302 HIV-TB co-infected
enrolled 2007–2009 reported an all cause mortality of
20% during an average follow up time of about one year
[6]. Among our 11 HIV-TB coinfected patients from
Sub-Saharan Africa only one died, despite longer follow
up times. This could be explained by early initiation of
ART, which was shown to be the strongest factor pro-
tecting from death in the study from Uganda.
There was a rather high number of loss to follow-up
seen in the HIV-TB patients in this cohort. Probable
reasons were that a substantial part of the subjects were
migrants living only temporary in Helsinki. Also IDUs
might have a more unregular living situation compared
to other residents.
The average duration of TB treatment was nearly 1
year. This cannot be explained by drug resistance, as
only two cases of MDR TB were diagnosed. Instead, this
seems to reflect the fact that most of the TB cases were
treated before year 2006, when the first national Finnish
guideline for TB treatment was published, which recom-
mended shorter treatments than earlier. Until that there
had been a tradition of long treatment durations in
Finland.
The small number of deaths in each subgroup has to be
considered when interpreting factors affecting mortality.
The all-cause mortality of HIV-TB co-infections in our co-
hort during an average follow up time of 9 years is 30%.
However, none of these 16 deaths were directly related to
TB. Among the 16 fatalities, 14 were Finnish males. The
all-cause mortality of Finnish males with HIV-TB
co-infection was 59%. The reason for this high mortality
rate is most likely an accumulation of other risk factors of
early death, such as heavy alcohol consumption, smoking,
injecting drug use and psychiatric illness. To reduce the
mortality rate in this group, active follow-up and multidis-
ciplinary social and psychiatric support could be useful. On
the other hand, among HIV-positive females and migrants,
Table 3 M. tuberculosis genotypes
Spoligotype Octal Code Frequency %
SIT53 777777777760771 7 13.2
SIT42 777777607760771 5 9.4
SIT1 000000000003771 3 5.6
SIT89 674000003413771 3 5.6
SIT149 777000377760771 1 1.9
SIT262 774777777420771 1 1.9
F286 773637777413771 1 1.9
F351 767777777740771 1 1.9
F373 777777657413771 1 1.9
SIT102 777703777760771 1 1.9
SIT106 776177400000171 1 1.9
SIT144 770000003760771 1 1.9
SIT1815 677777606760771 1 1.9
SIT2023 777737777720171 1 1.9
SIT2088 777777737760731 1 1.9
SIT2493 777773606060731 1 1.9
SIT256 777777777413671 1 1.9
SIT2724 774737777420771 1 1.9
SIT345 777000377760731 1 1.9
SIT49 777777777720731 1 1.9
SIT50 777777777720771 1 1.9
SIT75 777767777720771 1 1.9
SIT932 777777663760731 1 1.9
SIT937 777777777013771 1 1.9
NA NA 15 28.3
Total 53 100
Distribution of M. tuberculosis genotypes in HIV patients with active
TB infection. NA not available
Table 4 Outcomes of TB treatment
Treatment outcomes n %
Treatment completed/Cured 35 66.0
Treatment failure 0 0
Died during treatment 3 5.7
Default 3 5.7
Transfer out 5 9.4
Data not available 7 13.2
Total 53 100
The outcomes of the TB treatment of the HIV-TB co-infected patients in our
cohort presented according to WHO’s definitions
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TB-infection does not seem to affect their long-term
survival.
The benefits of isoniazid preventive therapy (IPT) for
latent tuberculosis has remained controversial as most
of the randomized trials showing efficacy of this strategy
where conducted in Africa before the beginning of
highly active antiretroviral therapies [19–21]. The recent
TEMPRANO study from Ivory Coast showed that 6
months of IPT has a durable protective effect in redu-
cing mortality in HIV-infected, even in people with high
CD4 cell counts and who have started ART [22, 23].
HIV cohort studies from Switzerland and the UK have
shown a significant reduction in incidence of active TB
after treatment of latent TB [4, 5]. However, the number
needed to treat to avoid one case of active TB was 15
and among those with ART as high as 35 [4]. During the
time period of our study, IPT was not routinely used to
prevent TB in our center.
Conclusions
To reduce the negative health effects of HIV-TB
co-infections in Finland and similar high-income
countries, the most important means are early diag-
nosis and treatment of both HIV and tuberculosis. It
is important to identify those HIV-patients with high
TB-risk to be able to detect active TB infections as
early as possible based on symptoms, chest x-ray,
sputum samples and biopsy of enlarged lymph nodes.
The treatment results of TB and the long-term prog-
nosis are generally good. However, for non-migrant
males with HIV-TB co-infection, the all-cause mortality is
unacceptably high and special efforts are needed to
address this problem.
Abbreviations
HUS: Hospital District of Helsinki and Uusimaa; IDU: Injecting drug user;
IGRA: Interferon gamma release assay; IPT: Isoniazid preventive therapy;
LTBI: Latent tuberculosis infection; NTM: Nontuberculous mycobacterium;
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Total 53 16 37
Sex 0.031
Male 36 15 21 1
Female 17 1 16 0.15 (0.019–1.10)
Mode of HIV-transmission 0.58
IDU 13 7 6 1.71 (0.53–5.52)
MSM 9 4 5 1.85 (0.49–7.02)
Heterosex 29 5 24 1
Country of birth 0.14
Finland 26 14 12 4.65 (0.61–35.5)
Sub-Saharan Africa 11 1 10 1
Other 15 1 14 1.3 (0.081–21.5)
Time of TB diagnosis 0.066
> 6months after HIV diagnosis 32 13 19 3.07 (0.87–10.8)
< 6 months from HIV diagnosis 29 3 26 1
MDR TB 2 0 2
MAC co-infection 5 1 4
TB recurrence 1 0 1
Age at TB diagnosis, years, mean (range) 38.9 (20–61) 42.9 (26–61) 37.2 (20–56) 1.06 (1.00–1.13) 0.036
CD4 at TB diagnosis, mean (range) 203 (5–859) 258 (5–854) 181 (9–859) 1.00 (0.99–1.00) 0.27
CD4 nadir, mean (range) 131 (1–471) 118 (1–471) 137 (9–458) 1.00 (0.99–1.00) 0.90
Characteristics of HIV-TB co-infected patients grouped base on whether they have died or are alive at the end of the follow-up period. Log-rank test was used to
calculate p-values for categorical variables and Wald test (Cox model) for continuous variables. Hazard ratios and their 95% confidence intervals were calculated
using Cox model. Hazard ratios for age and CD4 at time of TB diagnosis are per unit increase
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